PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care

Core Viewpoint - Veris Health Inc. has been awarded a $1.8 million grant from the National Institute on Minority Health and Health Disparities to optimize its Cancer Care Platform for medically underserved cancer patients [1][2]. Group 1: Grant and Research Focus - The two-year grant will fund research aimed at enhancing the Veris Cancer Care Platform to address the needs of cancer patients facing language barriers, limited access to technology, and socioeconomic disparities [1]. - The research project is titled "Bridging the Gap: Enhancing Cancer Care for Underserved Populations with the Veris Health Cancer Care Platform" [1]. Group 2: Company and Technology Overview - Veris Health Inc. specializes in personalized cancer care through remote patient monitoring using implantable biologic sensors and connected external devices [2]. - The Veris Cancer Care Platform includes features such as remote physiological data collection, symptom reporting, telehealth capabilities, and electronic health record integration [3]. Group 3: Strategic Implications - The NIH grant is considered important non-dilutive funding that supports Veris's commercial strategy, including regulatory clearance and the launch of its implantable physiological monitor [2]. - The grant aligns with PAVmed's long-term strategy to ensure that its subsidiaries, like Veris, are independently financeable while leveraging shared infrastructure [2].